ArticleBMC pulmonary medicine2026
Unexpected elevation of β-hCG in EGFR-mutant lung adenocarcinoma: a case study and implications for clinical practice.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeta-human chorionic gonadotropin (β-hCG) is frequently overexpressed in germ cell and trophoblastic tumors as well as various solid tumors; however, the presence of high levels of serum β-hCG is very rare in patients with non-small cell lung cancer. CASE DESCRIPTION: This report serves as a case study of an 84-year-old, non-smoking female who was diagnosed with advanced lung adenocarcinoma with bone and pleural metastases. The serum and pleural fluid β-hCG levels were significantly increased (2,618 mIU/ml and > 10,000 mIU/ml, respectively). Next-generation sequencing of the cancerous lung tissue revealed a mutation in the epidermal growth factor receptor (EGFR) gene, consistent with a deletion of exon 19. The patient was treated with gefitinib, an EGFR tyrosine kinase inhibitor, which resulted in a partial response. Unfortunately, during treatment, the patient developed interstitial lung disease and a pulmonary infection. Despite receiving treatment with steroids and antibiotics, the condition worsened, and the patient ultimately succumbed to the illness and passed away. The overall survival was 77 days.
conclusionsThis is the first report of pulmonary adenocarcinoma with both high serum β-hCG levels and an EGFR mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.